GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced on August 26, 2026, that it has entered into a warrant inducement agreement with an existing institutional investor. The agreement provides for the immediate exercise of existing warrants to purchase up to 5,697,628 shares of common stock at an exercise price of $0.64 per share, generating gross proceeds of approximately $3,646,482 before fees and expenses.
In consideration for the immediate exercise, the investor will receive new unregistered warrants to purchase up to 11,395,256 shares of common stock, also with an exercise price of $0.64. These new warrants will become exercisable upon shareholder approval of the underlying shares, expected to be obtained after the closing, and will expire five years from that approval date. The transaction is expected to close on or about August 27, 2026, subject to customary conditions.
The company intends to use the net proceeds for working capital and general corporate purposes. This infusion of capital comes at a critical time for GeoVax as it advances its lead program, GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The company has announced plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, with the goal of addressing global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.
Beyond infectious diseases, GeoVax is also developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings.
This financing is a strategic move to strengthen the company's balance sheet as it prepares for late-stage clinical trials. The additional capital is expected to support the company’s operations through significant milestones, including the initiation of the Phase 3 trial for GEO-MVA and continued development of its oncology pipeline.
The private placement of the new warrants and underlying shares is being made in reliance on exemptions from registration under the Securities Act of 1933, as amended, and Regulation D. As a result, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption.
GeoVax continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. The company's ability to secure this immediate funding reflects investor confidence in its programs and its commitment to addressing critical public health needs.
For more information about GeoVax and its programs, visit www.geovax.com.
